Opiant Pharmaceuticals (NASDAQ:OPNT) Rating Lowered to Market Perform at Northland Securities

Opiant Pharmaceuticals (NASDAQ:OPNTGet Rating) was downgraded by analysts at Northland Securities from an “outperform” rating to a “market perform” rating in a research report issued to clients and investors on Wednesday, The Fly reports.

Separately, Cantor Fitzgerald lowered Opiant Pharmaceuticals to a “neutral” rating in a report on Tuesday.

Opiant Pharmaceuticals Trading Down 0.0 %

Shares of OPNT opened at $20.08 on Wednesday. The business’s 50-day moving average price is $11.92 and its 200-day moving average price is $12.04. Opiant Pharmaceuticals has a twelve month low of $7.34 and a twelve month high of $37.71. The stock has a market cap of $103.61 million, a PE ratio of -3.06 and a beta of 0.51. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.60.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of OPNT. HealthInvest Partners AB grew its holdings in shares of Opiant Pharmaceuticals by 1,066.7% during the second quarter. HealthInvest Partners AB now owns 210,000 shares of the technology company’s stock worth $2,518,000 after purchasing an additional 192,000 shares in the last quarter. Ovata Capital Management Ltd purchased a new stake in Opiant Pharmaceuticals in the first quarter worth approximately $2,525,000. Apis Capital Advisors LLC boosted its stake in Opiant Pharmaceuticals by 75.0% in the second quarter. Apis Capital Advisors LLC now owns 196,000 shares of the technology company’s stock worth $2,350,000 after buying an additional 84,000 shares in the last quarter. Acadian Asset Management LLC boosted its stake in Opiant Pharmaceuticals by 62.0% in the first quarter. Acadian Asset Management LLC now owns 116,478 shares of the technology company’s stock worth $2,494,000 after buying an additional 44,562 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in Opiant Pharmaceuticals by 60.1% in the first quarter. Dimensional Fund Advisors LP now owns 106,682 shares of the technology company’s stock worth $2,285,000 after buying an additional 40,031 shares in the last quarter. Hedge funds and other institutional investors own 36.12% of the company’s stock.

About Opiant Pharmaceuticals

(Get Rating)

Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders.

See Also

The Fly logo

Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.